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SUMMARY 
 
Accurate patient positioning and routine computed tomography (CT) scans are critical components of 
proton therapy. Cone-beam CT (CBCT) has recently become available as an alternative to verification 
CT. This study describes the first clinical investigation of CBCT and deformable registration in adaptive 
lung proton therapy. 
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ABSTRACT 
 
Purpose: An adaptive proton therapy workflow using cone-beam computed tomography (CBCT) is 
proposed. It consists of an online evaluation of a fast range-corrected dose distribution based on a 
virtual CT (vCT). This may be followed by more accurate offline dose recalculation on the vCT 
which may trigger a rescan CT (rCT) for replanning. 
 
Methods and Materials: The workflow was tested retrospectively on twenty consecutive lung cancer 
patients. A diffeomorphic Morphons algorithm was used to generate the lung vCT, by deforming the 
average planning CT (pCT) onto the CBCT. An additional correction step was applied to account for 
anatomical modifications that cannot be modeled by deformation alone. A set of clinical indicators for 
replanning were generated based on water equivalent thickness (WET) and dose statistics, and 
compared to those obtained on a rCT. The fast dose approximation consisted of warping the initial 
planned dose onto the vCT based on changes in WET. Potential under/over-ranges were assessed as 
variation in WET at the target’s distal surface. 
 
Results: The range-corrected dose from the vCT reproduced similar clinical indicators as the rCT. 
The workflow performed well under different clinical scenarios: atelectasis, lung reinflation and 
different types of tumor response. Between vCT and rCT, we found a difference in the measured 95% 
percentile of the over-ranges distribution of 3.4±2.7mm. The limitations of the technique consisted of 
inherent uncertainties of deformable registration and drawbacks of CBCT imaging. The correction 
step was adequate when gross errors occurred but could not recover subtle anatomical or density 
changes in tumors with complex topology. 
 
Conclusions: A proton therapy workflow based on CBCT provided similar clinical indicators as rCT 
on lung patients with considerable anatomical changes. 
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1. INTRODUCTION 
 
Lung cancer is the leading cause of cancer-related death in the United States and worldwide. Modern 
radiotherapy techniques allow dose escalation1,2 and reduced injuries to normal tissues3-6. Proton 
therapy offers better dose localization than that achieved by conventional photon therapy.7-11 Proton 
dose distribution, however, is highly sensitive to changes in patient geometry, especially in the 
lungs.12 For example, interfractional tumor enlargement or development of atelectasis increase density 
along the beam path and shorten beam penetration. The under-ranging can potentially reduce target 
coverage. Conversely, tumor regression reduces density along the beam path and increases beam 
penetration. The over-ranging may result in unplanned dose to otherwise spared organs distal to the 
tumor volume. Therefore, accurate patient positioning and regular evaluation computed tomography 
(CT) scans are critical components of proton therapy.13 Replanning will be required if the new dose 
distribution based on evaluation CTs compromises target coverage and/or exceeds tissue tolerance. 
 
Volumetric imaging afforded by on-board cone-beam CT (CBCT) is an alternative to routine CT 
imaging and may play an important role in adaptive radiation therapy (ART). The advantages of on-
board CBCT are threefold: (1) it offers highly accurate patient positioning in three dimensions;14,15 (2) 
it enables daily monitoring of the patient in the treatment position; and (3) and it facilitates rapid 
assessment of the “dose of the day”.16-18 
 
We propose an ART workflow using on-board CBCT where replanning is triggered after three 
decision-points (Fig. 1). First, a fast range-corrected dose distribution based on water equivalent 
thickness (WET) is calculated on a virtual CT (vCT) derived from the CBCT.19 When significant 
dosimetric changes are observed, treatment may continue if normal tissue dose limits are not exceeded 
and after consultation with a physician. However, an offline review is triggered for a full dose 
recalculation on the vCT. If the dosimetric impact is still evaluated as significant, a rescan CT (rCT) is 
scheduled. If dosimetric changes are confirmed on the rCT, a replan is triggered. We retrospectively 
evaluated this workflow for twenty consecutive lung cancer patients summarizing common radiation-
induced changes in the lung and critically assessed the workflow. The rCT was used as the gold-
standard to gauge the accuracy of the vCT. To our knowledge, this study is the first clinical 
investigation of CBCT in adaptive lung proton therapy. 
 
2. METHODS AND MATERIALS 
 
2.1. Patient selection and data acquisition 
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Data from twenty consecutive patients treated for lung malignancies were included in this 
retrospective study. All patients underwent passive scattering proton therapy (PSPT) using two 
treatment fields with a median dose of 66.3Gy[CGE] (range:40-66.6Gy[CGE]) in a median of 
1.8Gy/fraction (range:1.5-4Gy/fraction). The patient cohort included a variety of tumor sizes, 
locations and anatomical changes that occurred throughout the treatment course (Table 1). The 
imaging protocol consisted of a 4D PET/CT for treatment planning, CBCT and rescan 4D CT 
acquired in treatment position for verification during the course of treatment. The proton-gantry 
mounted CBCT system (Ion Beam Applications SA, Ottignies-Louvain-la-Neuve, BE) has a source-
to-axis distance of 288.4cm, detector-to-axis distance of 58.6cm and a maximum field-of-view (FoV) 
of 34cm; the images were acquired in half-scan mode at 110kVp and 1142mAs. The CBCTs were 
reconstructed with a resolution of 1.33×1.33×2.5mm3 using the open-source Reconstruction Toolkit 
(RTK).20 The average phase of the 4D CT was used for dose calculations. One pair of CBCT and rCT 
at mid-treatment was selected for evaluation for each patient. The chosen rCT and CBCT scans were 
acquired on the same day for 17 patients; for 3 they were acquired within 2 days of each other. 
 
2.2. Virtual CT and image correction 
 
The CBCT was rigidly aligned to the planning CT (pCT) and the diffeomorphic Morphons 
deformable image registration (DIR) algorithm available in the open-source REGGUI package was 
subsequently applied to register the pCT to the CBCT.21 This method was previously validated for 
head and neck cancer patients.16,17 
 
Some anatomical changes in the thorax cannot be modeled by deformation alone. The situations are 
diverse, but include changes within the lung (such as atelectasis and pleural effusion) and different 
tumor responses to treatment (such as regression of infiltrating tumors and erosion22). Therefore, a 
semi-automatic correction step was applied to the vCT for these anatomical modifications. This step 
consists of a watershed-cuts algorithm23,24 combined with an exclusive OR logical operator and a 
classifier25,26 to identify regions showing significant intensity mismatch between vCT and CBCT. 
When appropriate, the vCT intensities were replaced by the bulk value of lung or tissue based on 
thresholding of the CBCT intensities. This algorithm was validated in-house27; technical details of the 
implementation can be found as supplementary material. 
 
2.3. Clinical indicators: WET and dose warping 
 
A complementary set of clinical indicators, based on WET and dose, that support the replanning 
decision-making, were used to estimate the impact of anatomical changes on the treatment objectives. 
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Variation in WET on the distal surface of the target is a good surrogate for potential under/over-
ranges. Changes in range were estimated by computing the difference between the WET from the pCT 
and vCT (i.e. WETpCT>WETvCT corresponds to over-ranging and WETpCT<WETvCT to under-ranging). 
In PSPT compensator smearing is used to ensure target coverage in presence of errors in patient 
positioning and motion.28 Therefore, potential under-ranges are partially taken into account by the 
compensator; thus, for under-ranges a morphological dilation using the same radius as the 
compensator is applied on the pCT-based WET map before computing the difference with the vCT-
based WET map to identify under-ranges not accounted for in smearing. Quantitative measurements 
of the 2D WET difference maps at the PTV distal surface (per beam) for the pCT and vCT were 
calculated as clinical indicators, which include the percentage of pixels with under/over-ranges larger 
than 3mm (WETunder>3mm/WETover>3mm) and the 95% percentile of the under/over-range distribution 
(WETunder-95%/WETover-95%). 
 
Complementary to the WET analysis, it is necessary to evaluate the dosimetric impact of under/over-
ranging, particularly for OAR. Online dose review requires a fast dose recalculation tool; thus we 
validated in-house a fast range-corrected dose approximation method29 by warping the original dose 
onto the vCT based on changes in the 3D WET maps between the vCT and pCT. Doses were 
recalculated using Eclipse version 11.0 (Varian Medical Systems, Palo Alto, CA). The following 
abbreviations are used to identify the different doses: pCT dose (DpCT), vCT warped dose (DvCT-WET), 
vCT recalculated dose (DvCT) and rCT recalculated dose (DrCT). DVHs and dosimetric statistics 
representative of target coverage and OAR tolerances used in-house to trigger replanning were chosen 
as dose indicators. These were for PTV and iCTV the V95% and V99%, respectively, with a threshold of 
3% change in the rCT. For OARs the dose tolerances used were: for heart, Dmax=72Gy, V45Gy<35% 
and V30Gy<50%; for esophagus, Dmax=70Gy and V55Gy<30%; for cord (and cord+5mm), 
Dmax=50Gy(65Gy); and for brachialplexus, Dmax=66Gy. The iCTV/PTV contours were rigidly 
propagated while the OARs were propagated using DIR. 
 
3. RESULTS 
 
3.1 Case studies of different anatomical changes 
 
3.1.1 Lung changes 
 
Atelectasis is the collapse of lung that is sometimes reversible. PT#1 developed partial atelectasis at 
the upper left lobe during week two (Fig. 2) resulting in increased WET along the beam paths and 
subsequent under-ranging (WETunder-95%=10.4/12.3mm for LPO1/LPO2 field). Tumor coverage was 
compromised and a higher dose was delivered to the esophagus (Dmax from 50Gy to 71/71/68Gy for 
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DvCT-WET/DvCT/DrCT) which triggered immediate replanning. The vCT predicted similar dosimetric 
indicators as the rCT. 
 
When tumors regress, the previously blocked airway can reopen and reinflate the collapsed lung 
(PT#3, Fig. 3). Lung reinflation reduced the WET along the beam path, and caused beam over-
ranging (WETover-95%=41.4/44.1mm for RPO/PA field). The change in dose distribution compromised 
tumor coverage (iCTV ∆V99%=-27/-27/-13% for DvCT-WET/DvCT/DrCT), which triggered replanning. The 
predicted loss of coverage was higher in the vCT than in rCT, which can be attributed to the partial 
truncation of the CBCT at the beam entrance (see section 3.1.3). 
 
3.1.2: Tumor changes 
 
Different tumor response scenarios were identified and detailed below. 
 
Infiltrating tumors 
 
For PT#14, the GTV decreased from 4.1 to 2.7cm in diameter after four weeks of treatment (Fig. 3). 
The uncorrected vCT resulted in DIR errors of the lung tissue between the tumor and chest wall. After 
applying the correction algorithm, the clinical indicators were nearly identical between vCT and rCT 
(iCTV ∆V99%=-5/-7/-6% for DvCT-WET/DvCT/DrCT). 
 
Tumor regression 
 
When tumors regress, the topological changes may not be handled by DIR alone. In PT#2 a 22.3mm 
cavity appeared within the original tumor volume (Fig. 2). Its size and location were accurately 
identified and accounted for by the vCT correction step. The reduction in WET along the beam path 
resulted in beam over-ranging to the heart (WETover-95%=24.6/25.2mm for RPO1/RPO2 field, Figs. 4 
and 5). Dosimetric indicators between vCT and rCT were similar (Fig. 4), i.e., decreased iCTV 
coverage (iCTV ∆V99%=-7/-6/-8% at DvCT-WET/DvCT/DrCT), and increased dose to the cord (Dmax from 
45 to 52/52/49Gy for DvCT-WET/DvCT/DrCT) and the heart (V45Gy from 25% to 31/31/35% for DvCT-
WET/DvCT/DrCT). 
 
Changes in tumor density 
 
PT#20 had both regression and changes in tumor density; the average intensity of the GTV decreased 
from 30 to -110HU between pCT/vCT and rCT, corresponding to a local WET variation of 
approximately 7mm. The vCT retained the HUs from the pCT and underestimated the change in 
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proton range, i.e., WETover>3mm=27.0/40.7% for vCT/rCT (RPO1 field). Regardless of the differences 
in WET between the vCT and rCT, identical reduction in dose coverage was detected in the DVHs. 
 
Moderate shrinkage/enlargement 
 
Moderate tumor regression was here defined as a visually apparent change in tumor volume less than 
25% of its original GTV. An example is PT#11, who has focal shrinkage resulting in modest beam 
over-ranging (WETover-95%=8.5/7.5mm for AP/RPO field), and an increase in dose to the cord (Dmax 
from 30 to 36/37/37Gy for DvCT-WET/DvCT/DrCT). PT#16 was the only case of tumor enlargement 
during radiation treatment; the diameter increased ~5mm along the beam path. Because of the 
complex organ geometry at the mediastinum, both beam under/over-ranging were observed (i.e., 
WETunder-95%=1.1mm and WETover-95%=3.6mm for RPO field), resulting in increased dose to the cord 
(Dmax from 35 to 46/47/40Gy for DvCT-WET/DvCT/DrCT), and a right shift of iCTV/PTV DVH curves. In 
these two cases the vCT and rCT offered similar clinical indicators with DIR alone. 
 
3.1.3: Other factors affecting clinical indicators 
 
In addition to DIR errors, setup variations and differences in the respiratory pattern between CBCT 
and rCT scans can result in differences between DvCT-WET/DvCT and DrCT.  This implies that different 
clinical indicators are being extracted, and can, therefore, create false positive/negative triggers for 
offline review. Our online workflow was less robust for patients in whom the magnitude of dose 
differences arising from setup variations was comparable to those arising from internal anatomical 
change. For PT#13, tumor shrinkage was well recovered by DIR; however the position of the main 
bronchi was shifted superiorly in rCT in comparison to the CBCT (Fig. 3). The movement of the main 
airway cause different predictions of target coverage (iCTV ∆V99%=+3/+1/-4% for DvCT-
WET/DvCT/DrCT). WET difference maps were also affected: the magnitude of WETover-95% was small but 
the 2D WET maps gave different indicators (WETover>3mm was 18.8/46.6% for vCT/rCT for PT#19 
RPO field, see Fig. 5). Clinically, none of these patients required replanning as the dosimetric changes 
were generally small and the effects averaged out during the course of treatment.  
 
Setup errors should not be confused with systematic drift of tumor position through the treatment 
course. For PT#5, the primary tumor shifted in the inferior direction, and this was consistent between 
the CBCT and rCT. DIR accurately described the change in tumor position, but the modest change in 
WET had minimal effect on target coverage or dose to OAR. 
 
Due to FoV limitations, a minority of CBCTs did not encompass the entire exterior of the patient 
body at the beam entrance (Fig. 2 and 3). For PT#4, the CBCT truncation resulted in overestimation 
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of over-ranging of the RPO field (WETover-95%=19.1/11.0mm for rCT/vCT), but the overall changes in 
range and dosimetry were small (Fig. 4). Nevertheless, uncorrected truncation may in some cases lead 
to inaccurate clinical indicators (PT#3: iCTV ∆V99%=-27/-27/-13% and, PT#17: iCTV ∆V99% =0/0/-
5% for DvCT-WET/DvCT/DrCT). 
 
3.2 General results 
 
Eighteen of the twenty patients exhibited tumor regression resulting in over-ranging of the proton 
beams; two showed considerable under-ranging. These were cases of atelectasis (PT#1) and tumor 
enlargement (PT#16). For all patients, the average absolute difference in WETover-95% and WETover>3mm 
between vCT and rCT were 3.4±2.7mm and 12±12%, respectively. Figure 5 shows examples of WET 
and WET difference maps. WET difference maps identified the same regions of under/over-ranging 
for all patients with large anatomical changes. This was true even for PT#8 and PT#20, in spite of the 
full magnitude of the over-ranging not being fully recovered due to limitations of the corrected vCT to 
reproduce complex shrinkage and/or density changes (Fig. 5). In cases of smaller changes or setup 
variations, the WET difference maps were less uniform. In general, values of WETover-95% needed to 
exceed 15mm before significant dosimetric changes could be detected. The most common issues that 
could lead to a replan were loss of tumor volume coverage, increase in maximum dose to the cord, 
and over-ranging of dose into the heart. 
 
4. DISCUSSION 
 
In proton therapy, accurate Hounsfield units are a requirement to make clinical decisions for ART. 
CBCT plays an important role in image-guided therapy, and vCTs is one step in that direction and 
may play a complementary role to rCT. 
 
In terms of WET information, although the vCT may not reproduce identical WET maps, it identifies 
the same trends as the rCT regarding the effect of the WET changes. 90% of the fields with WETunder-
95%/WETover-95% larger than 10mm were properly identified as such from the vCT. The dose warping 
method reproduced similar clinical indicators for patients with considerable changes that may trigger 
a replan. The most common issue was loss of target coverage of the iCTV. For PT#1, PT#2 and 
PT#14, the impact to OARs was detected (esophagus, heart/cord and cord respectively). For PT#8, the 
changes in OAR dose were not properly detected, while for PT#20 an increase in cord dose was 
incorrectly detected. When smaller changes occurred, differences in OAR dose were also detected 
(PT#11, PT#12 and PT#16), but some false positives/negatives occurred for loss of target coverage 
(PT#13, PT#15 and PT#17). Variations in setup can result in overestimation (PT#9) and 
underestimation (PT#19) of over-ranging, but with minimal dosimetric impact. In general, OAR doses 
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were maintained within tolerance; however, special care should be given to fields that point towards 
an OAR, such as lateral oblique fields that may range out at the heart (PT#2, PT#7 and PT#12). 
 
An important conclusion taken from this retrospective investigation was the necessity to evaluate 
multiple parameters during the ART decision-making process: changes in WET, qualitative review of 
images and dose distributions, DVHs and corresponding dose-statistics. Flags raised by a single 
indicator should be backed by additional evidence. For example, iCTV-V99% statistic was quite 
sensitive even when the DVHs did not reflect major changes. In cases where the anatomical changes 
are small the decision to replan should not be based on individual scans, but rather on continued 
monitoring. Smaller changes can in fact be comparable to setup errors and may average out. 
 
The limitations of the proposed workflow were identified through an evaluation using a diverse cohort 
of patients. DIR has inherent uncertainties and associated errors, and traditional algorithms are not 
adequate when tissue appears/disappears (such as atelectasis). If unaccounted for, such situations 
result in significant errors in WET/range estimation. The correction step works well for gross 
registration errors, but cannot recover complex changes in tumor topology. When applying the 
method prospectively and if the correction step is not adequate, manual adjustments to the vCT may 
be necessary during the second decision-making point (i.e., offline review of vCT). Using CBCT 
directly for dose recalculation is a viable alternative to remove the errors associated with DIR. Despite 
the vast work on directly using CBCT in conventional photon therapy14,30 and/or to improve CBCT 
image quality31,32, its usability is still limited in proton therapy18,33 and therefore the corrected vCT is a 
good interim solution. For smaller registration errors, we identified two common patterns of failure: 
first, the interface of lung-tissue-bone at the posterior rib wall due scatter artifacts, and second, the 
positioning of the scapula (which can often move in and out of the path of lateral oblique fields). 
From a clinical perspective, two scenarios are possible with DIR errors. The first is a false positive 
trigger, i.e., the dose calculated on the vCT indicated a change in dosimetry when there is none. The 
outcome is an unnecessary CT scan to confirm the findings. The other is a false negative trigger, i.e., 
the dose calculated on the vCT failed to detect the change in dosimetry. While this scenario poses a 
bigger risk it is unlikely to occur. Higher DIR errors are associated with larger anatomical changes, 
and in such cases variations in dosimetry are usually still predicted even if with a different magnitude. 
 
The use of CBCT instead of rCT has its own associated challenges. First, subtle changes in density of 
lung tissues between planning and verification (PT#20) were undetectable on CBCT but apparent on 
rCT. Second, the limited FoV and artifacts caused by the couch may result in incomplete information 
of the external contour. This was problematic for some lateral oblique fields (10% of fields); 
regardless, it can be avoided by closely matching the patient geometry near the beam entrance during 
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image acquisition. This is not a limitation of the proposed workflow for CBCT systems with larger 
FoVs. 
 
We established that a vCT is comparable to rCT; the next step is to test the workflow on a larger 
cohort and transition the workflow to clinical routine. The clinical indicators investigated here were 
empirically sensible; yet further investigations are required for defining the appropriate action 
threshold for replanning. On the technical side, improvement of the workflow to minimize its current 
limitations is a priority, which includes investigating lung-specialized DIR algorithms,34 automatic 
segmentation validation,19 improvement of CBCT image quality32 and integration with TPS or using 
more accurate dose calculations.35 
 
5. CONCLUSIONS 
 
We retrospectively evaluated a novel workflow to quantitatively assess WET and dose distributions 
using CBCT for proton therapy. This workflow was shown to provide similar clinical indicators as 
rCT on patients with considerable interfractional anatomical changes. 
 
FIGURE LEGENDS 
 
Table 1- Patient characteristics. 
 
Figure 1- Workflow for ART. A corrected vCT was created using pCT-to-CBCT DIR, and the 
variation in WET between vCT and pCT was used to range-correct the planned dose. This process can 
be performed online to trigger an in-depth offline review of the vCT (and rCT) if deemed necessary. 
 
Figure 2- Images used and generated by the workflow for PT#1 (atelectasis), PT#2 (large tumor 
shrinkage) and PT#4 (small tumor shrinkage). A consistent soft tissue window level was used for CT 
datasets (except the CBCT). For PT#1 and PT#2, the vCT needed the correction step (region defined 
by the red contour). For PT#4, DIR alone recovered the changes well; however, CBCT truncation 
affected the similarity between vCT and rCT. 
 
Figure 3- Images used and generated by the workflow for PT#3 (lung reinflation), PT#14 (regression 
of infiltrating tumor) and PT#13 (shrinkage and changes in breathing pattern). A consistent soft tissue 
window level was used for CT datasets (except the CBCT). For PT#3 and PT#14, correction of the 
vCT was necessary (region defined by the red contour). For PT#13, DIR was able to recover the 
tumor shrinkage; however, visible differences in setup occur between vCT and rCT, particularly in the 
position of the main airways (yellow arrow). 
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Figure 4- (A) Color overlay of the CTs and corresponding dose distributions and (B) DVHs for PT#1, 
PT#2 and PT#4. For PT#1 the appearance of atelectasis increased the WET, resulting in under-
ranging and loss of iCTV coverage. For PT#2 the shrinkage of the GTV resulted in decreased WET, 
and thus in over-ranging and increase in dose delivered to the heart and cord. For PT#4 the changes in 
WET were small in spite of CBCT truncation, resulting in similar dose distributions and DVH curves. 
 
Figure 5- WET and WET difference maps for PT#2 (RPO1 field), PT#8 (PA field) and PT#19 (RPO 
field). 
 
REFERENCES 
 
1. Belderbos JSA, Heemsbergen WD, De Jaeger K, et al. Final results of a phase I/II dose escalation 
trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol 
Biol Phys 2006;66(1):126-134. 
 
2. Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is 
associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with 
chemoradiation: An analysis of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 
2012;82(1):425-434. 
 
3. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-
dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. 
Cancer 2005;103(10):2118-2127. 
 
4. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: A phase I-II 
dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable 
non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61(2):318-328. 
 
5. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with 
concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: Phase 
I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010;77(2):367-372. 
 
6. Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. Br J Cancer 2005;93(8):849-
854. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7. Simone CB 2nd, Rengan R. The use of proton therapy in the treatment of lung cancers. Cancer J 
2014;20(6):427-432. 
 
8. Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO) 
comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 
2012;7(1):165-176. 
 
9. Simone CB 2nd, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptive 
radiotherapy proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced 
head and neck cancer. Radiother Oncol 2011;101(3):382. 
 
10. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton 
radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in 
stage I or stage III non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65(4):1087-1096. 
 
11. Kesarwala AH, Ko CJ, Ning H, Xanthopoulos E, Haglund KE, O'Meara WP, Simone CB 2nd, 
Rengan R. Intensity-modulated proton therapy for elective nodal irradiation and involved-field 
radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric 
study. Clin Lung Cancer 2015;16(3):237-44. 
 
12. Berman AT, James SS, Rengan R. Proton beam therapy for non-small cell lung cancer: Current 
clinical evidence and future directions. Cancers. 2015;7(3):1178-1190. 
 
13. Wink KCJ, Roelofs E, Solberg T, et al. Particle therapy for non-small cell lung tumors: Where do 
we stand? A systematic review of the literature. Front Oncol 2014;4:292 
 
14. Yang Y, Schreibmann E, Li T, et al. Evaluation of on-board kV cone beam CT (CBCT)-based 
dose calculation. Phys Med Biol 2007;52(3):705. 
 
15. Grills IS, Hugo G, Kestin LL, et al. Image-guided radiotherapy via daily online cone-beam CT 
substantially reduces margin requirements for stereotactic lung radiotherapy. Int J Radiat Oncol Biol 
Phys 2008;70(4):1045-1056. 
 
16. Landry G, Desdes G, Zollner C, et al. Phantom based evaluation of CT to CBCT image 
registration for proton therapy dose recalculation. Phys Med Biol 2015;60(2):595-613. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17. Landry G, Nijhuis R, Dedes G, et al. Investigating CT to CBCT image registration for head and 
neck proton therapy as a tool for daily dose recalculation. Med Phys 2015;42(3):1354-1366. 
 
18. Veiga C, Alshaikhi J, Amos R, et al. Cone-beam computed tomography and deformable 
registration-based “dose of the day” calculations for adaptive proton therapy. Int J Particle Ther 
2015;2(2):404-414. 
 
19. Peroni M, Ciardo D, Spadea MF, et al. Automatic segmentation and online virtual CT in head- 
and-neck adaptive radiation therapy. Int J Radiat Oncol Biol Phys 2012;84:e427–e433. 
 
20. Rit S, Vila Oliva M, Brousmiche S, et al. The Reconstruction Toolkit (RTK), an open-source 
cone-beam CT reconstruction toolkit based on the Insight Toolkit (ITK). J Phys: Conf  Ser 2014: 489; 
012079. 
 
21. Janssens G, Jacques L, Orban de Xivry J, et al. Diffeomorphic registration of images with variable 
contrast enhancement. Int J Biomed Imaging 2011;2011(Mi):891585. 
 
22. Sonke JJ and Belderbos J. Adaptive radiotherapy for lung cancer. Semin Radiat Oncol 2010; 
20(2):94-106. 
 
23. Bernard G, Verleysen M, Lee JA. Incremental classification of objects in scenes: Application to 
the delineation of images. Neurocomputing 2015;152:45-57. 
 
24. Cousty J, Bertrand G, Najman L,Couprie M. Watershed cuts: minimum spanning forests and the 
drop of water principle. IEEE Trans Pattern Anal Mach Intell 2009;31(8):1362-1374. 
 
25. Freund Y, Schapire RE. Large margin classification using the Perceptron algorithm. Machine 
Learning 1998;37(3):277-296. 
 
26. Gallant SI. Perceptron-based Learning Algorithms. IEEE Trans Neural Netw 1990;1(2):179-191. 
 
27. XXX. The accuracy of deformable registration for adaptive lung proton therapy” Med Phys 2016 
(in review). 
 
28. Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy. 
Phys Med Biol 1984;29(5):553-66. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29. Park PC, Cheung J, Zhu XR, et al. Fast range-corrected proton dose approximation method using 
prior dose distribution. Phys Med Biol 2012;57(11):3555-3569. 
 
30. Guan H, Dong H. Dose calculation accuracy using cone-beam CT (CBCT) for pelvic adaptive 
radiotherapy. Phys Med Biol 2009;54(20):6239–6250. 
 
31. Li J, Yao W, Xiao Y, Yu Y. Feasibility of improving cone-beam CT number consistency using a 
scatter correction algorithm. J Appl Clin Med Phys 2013;14:167-176. 
 
32. Park Y-K, Sharp GC. Phillips J, Winey BA. Proton dose calculation on scatter-corrected CBCT 
image: feasibility study for adaptive proton therapy. Med Phys 2015;42(8):4449-4459. 
 
33. Kurz C, Dedes G, Resch A, et al. Comparing cone-beam CT intensity correction methods for dose 
recalculation in adaptive intensity-modulated photon and proton therapy for head and neck. Acta 
Oncologica 2015;54:1651-1657. 
 
34. Al-Mayah A, Moseley J, Velec M, Brock K. Toward efficient biomechanical-based deformable 
image registration of lungs for image-guided radiotherapy. Phys Med Biol 2011;56(15):4701-4713. 
 
35. Jia X, Schumman J, Paganetti H, Jiang SB. GPU-based fast Monte Carlo dose calculation for 
proton therapy. Phys Med Biol 2012;57(23):7783-7797. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1- Patient characteristics 
PT 
# 
Age 
(Y) 
G TNM 
Fields 
(gantry angle/name) 
ViCTVa 
(cm3) 
FrCT/Ftb Characteristics at verification scan 
Tumour motion: 
SI/LR/APc (mm) 
pCT rCT 
1 85 M T3N2M0 175(LPO1) & 135(LPO2) 130 9/37 Atelectasis 6/6/4 6/7/5 
2 71 F T3N2M0 210(RPO1) & 220(RPO2) 410 20/37 Large tumor shrinkaged 8/5/5 10/4/4 
3 68 F T4N2M0 220(RPO) & 180(PA) 280 4/30 Lung reinflation 10/4/10 12/3/2 
4 69 M T4N2M0 180(PA) & 220(RPO) 280 21/37 Small tumor shrinkage/setup error 5/1/3 5/1/3 
5 72 M T3N3M0 180(PA) & 10(RAO) 260 8/27 Tumor position drift 9/2/4 8/3/2 
6 81 M T4N0M0 180(PA) & 155(LPO) 320 9/37 Small tumor shrinkage/setup error 3/1/2 2/1/1 
7 77 M T2aN2M0 180(PA) & 200(RPO) 180 10/37 Small tumor shrinkage/setup error 7/3/2 5/2/2 
8 62 F T4N2M0 270(ASO) & 180(PA) 340 4/34 Large regression of infiltrating tumor 2/3/6 4/2/5 
9 64 M T2aN0M0 180(PA) & 155(LPO) 130 22/37 Small tumor shrinkage/setup error 4/2/2 4/1/3 
10 65 M T4N1M0 180(PA) & 150(LPO) 180 10/25 Small tumor shrinkage/setup error 5/3/4 8/3/4 
11 31 M T2aN2M0 0(AP) & 205(RPO) 200 20/37 Moderate tumor shrinkagee 7/2/5 7/4/4 
12 76 F T2bN0M0 180(PA) & 210(RPO) 150 20/37 Moderate tumor shrinkage 2/0/0 2/0/1 
13 71 M T3N2M0 180(PA) & 145(LPO) 190 21/25 Moderate tumor shrinkage 6/3/3 6/3/6 
14 65 F T4N0M0 180(PA) & 150(LPO) 500 20/37 Large regression of infiltrating tumor 2/2/2 1/0/0 
15 57 F T3N2M0 180(PA) & 224(RPO) 340 10/30 Moderate tumor shrinkage 3/2/0 3/3/1 
16 58 F T4N0M0 205(RPO) & 20(LAO) 580 15/33 Moderate tumor enlargement 6/6/4 2/1/1 
17 62 F T1aN2M1b 173(LPO) & 150(LPO) 100 5/37 Moderate tumor shrinkage 2/0/2 3/1/4 
18 67 M T3N1M0 0(AP) & 335(RAO) 330 20/30 Small shrinkage/setup error 3/3/3 5/3/3 
19 69 M T3N0M1b 180(PA) & 205(RPO) 310 7/16 Small shrinkage/setup error 2/2/2 1/1/1 
20 78 M T2aN0M1b 195(RPO) & 210(RPO) 140 9/15 Large tumor shrinkage; density changes 5/2/2 5/4/3 
aViCTV=volume of the iCTV 
bFrCT/Ft=treatment fraction at which rCT was acquired/total number of fractions 
cSI=superior-inferior; LR=left-right; AP=anterior-posterior 
dLarge tumor shrinkage = visually apparent change in tumor volume greater than 25% of its original GTV.  
eModerate tumor shrinkage = visually apparent change in tumor volume less than 25% of its original GTV.  
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